BioNTech's Supervisory Board announced on August 3 the appointment of Guido Oelkers, CEO of Swedish Orphan Biovitrum (Sobi) since 2017, as the company's next Chief Executive Officer, taking office by February 1, 2027 at the latest. He succeeds co-founder Ugur Sahin, who said in March 2026 that he and his wife and co-founder, chief medical officer Ozlem Tureci, would depart to launch a new mRNA-medicines biotech; a successor for Tureci's role is still being sought.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- BioNTech reports first pumitamig data in second-line lung cancerTuesday, October 27, 2026
- BioNTech says a breast-cancer trial met a modest PFS goalTuesday, October 27, 2026
- BioNTech says BNT113 missed its progression-free survival goalThursday, October 15, 2026
- Health Canada authorizes BioNTech XFG Comirnaty shotSunday, September 20, 2026